LENZ Therapeutics (LENZ) Total Current Liabilities (2020 - 2026)

LENZ Therapeutics (LENZ) has 7 years of Total Current Liabilities data on file, last reported at $25.8 million in Q1 2026.

• On a quarterly basis, Total Current Liabilities rose 201.16% year-over-year to $25.8 million in Q1 2026; TTM through Mar 2026 was $25.8 million, a 201.16% increase from a year earlier, with the FY2025 full-year figure at $21.2 million, up 103.6% from the prior year.
• Total Current Liabilities for Q1 2026 stood at $25.8 million, up from $21.2 million in the prior quarter.
• Over the last five years, Total Current Liabilities for LENZ reached as high as $25.8 million in Q1 2026 and fell as low as $7.7 million in Q3 2024.
• Historically, Total Current Liabilities has averaged $13.9 million across 5 years, with a median of $12.8 million in 2022.
• Across the five-year window, Total Current Liabilities plunged 54.63% in 2025 and jumped 201.16% in 2026, its largest moves.
• Year by year, Total Current Liabilities stood at $13.0 million in 2022, then surged by 41.95% to $18.5 million in 2023, then sank by 43.79% to $10.4 million in 2024, then surged by 103.6% to $21.2 million in 2025, then grew by 21.8% to $25.8 million in 2026.
• Per Business Quant data, the three most recent Total Current Liabilities figures were $25.8 million in Q1 2026, $21.2 million in Q4 2025, and $16.3 million in Q3 2025.